AstraZeneca (LON:AZN) Receives Buy Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a research report issued to clients and investors on Monday,Digital Look reports. They currently have a GBX 140 ($1.74) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s target price points to a potential downside of 98.75% from the company’s current price.

Several other brokerages have also recently commented on AZN. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a £140 ($174.19) price target on shares of AstraZeneca in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of GBX 7,935.67 ($98.74).

AstraZeneca Trading Down 0.1 %

LON AZN traded down GBX 10 ($0.12) during trading hours on Monday, reaching £111.70 ($138.98). The company’s stock had a trading volume of 6,044,899 shares, compared to its average volume of 46,410,563. The stock has a market cap of £173.13 billion, a P/E ratio of 3,546.03, a P/E/G ratio of 0.86 and a beta of 0.17. The firm has a fifty day simple moving average of £105.88 and a 200-day simple moving average of £115.38. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 52 week low of GBX 9,461 ($117.72) and a 52 week high of £133.88 ($166.58).

Insider Activity

In related news, insider Pascal Soriot purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were purchased at an average cost of £102.03 ($126.95) per share, for a total transaction of £2,040,600 ($2,539,007.09). Also, insider Tony Mok acquired 1,500 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($157.77) per share, with a total value of £190,200 ($236,655.47). Insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.